These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3145187)

  • 1. Prolactin release in polycystic ovarian syndrome.
    Minakami H; Abe N; Oka N; Kimura K; Tamura T; Tamada T
    Endocrinol Jpn; 1988 Apr; 35(2):303-10. PubMed ID: 3145187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A longitudinal study on the prognosis of ovulatory disturbance in teenage patients with high LH and normal FSH serum levels].
    Kimura K; Minakami H; Tamada T
    Nihon Naibunpi Gakkai Zasshi; 1988 Oct; 64(10):1088-101. PubMed ID: 3145220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin levels in the polycystic ovary syndrome.
    Milewicz A
    J Reprod Med; 1984 Mar; 29(3):193-6. PubMed ID: 6233421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity.
    Corenblum B; Taylor PJ
    Fertil Steril; 1982 Nov; 38(5):549-52. PubMed ID: 6813147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactin release in polycystic ovary.
    Falaschi P; del Pozo E; Rocco A; Toscano V; Petrangeli E; Pompei P; Frajese G
    Obstet Gynecol; 1980 May; 55(5):579-82. PubMed ID: 6768043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exaggerated prolactin response to thyrotropin-releasing hormone and metoclopramide in primary testicular failure.
    Spitz IM; LeRoith D; Livshin Y; Zylber-Haran E; Trestian S; Laufer N; Ron M; Palti Z; Schenker J
    Fertil Steril; 1980 Dec; 34(6):573-80. PubMed ID: 6778717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of bromocriptine on endocrine environment in the polycystic ovary syndrome].
    Huang HJ; Ishimaru T; Yamabe T
    Nihon Naibunpi Gakkai Zasshi; 1988 Apr; 64(4):265-78. PubMed ID: 3136040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relation between hyperprolactinemia and polycystic ovary syndrome].
    Hámori M; Szendei G; Kovács I; Somos P
    Zentralbl Gynakol; 1987; 109(8):481-6. PubMed ID: 3111126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern.
    Carmina E; Rosato F; Maggiore M; Gagliano AM; Indovina D; Jannì A
    Acta Endocrinol (Copenh); 1984 Jan; 105(1):99-104. PubMed ID: 6229966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin response after gonadotropin-releasing hormone in the polycystic ovary syndrome.
    Shoupe D; Lobo RA
    Fertil Steril; 1985 Apr; 43(4):549-53. PubMed ID: 3921411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary and ovarian responses to LHRH stimulation in women with clinical features of the polycystic ovary syndrome.
    Heineman MJ; Thomas CM; Doesburg WH; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):273-84. PubMed ID: 6430731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma patterns of LH, FSH and prolactin in rats with a polycystic ovarian condition induced by oestradiol valerate.
    Grosser PM; McCarthy GF; Robaire B; Farookhi R; Brawer JR
    J Endocrinol; 1987 Jul; 114(1):33-9. PubMed ID: 2821144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
    Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA
    J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depressed follicle-stimulating hormone, luteinizing hormone, and prolactin responses to the luteinizing hormone-releasing hormone, thyrotropin-releasing hormone, and metoclopramide test in endurance runners in the hard-training season.
    Ronkainen H
    Fertil Steril; 1985 Dec; 44(6):755-9. PubMed ID: 3935485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory dynamics of bioactive and immunoreactive prolactin in polycystic ovary syndrome.
    Anderson RE; Ben-Rafael Z; Flickinger GL; Meloni F; Barnes RB; Rosen GF; Lobo RA
    Fertil Steril; 1988 Feb; 49(2):239-43. PubMed ID: 3276562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome.
    Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Fossati P
    Fertil Steril; 1985 Sep; 44(3):356-60. PubMed ID: 3161758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.